Shots:

• The FDA’s BT designation is based on P-III ECHELON-2 study results assessing Adcetris + CHP vs CHOP (cyclophosphamide- doxorubicin- vincristine- prednisone) in 450 patients with CD30+ T-cell lymphoma across North America- EU and Asia
• The P-III ECHELON-2 study results: met it's 1EPs & 2EPs; improvement in PFS- superior OS; CRR and ORR were statistically significant in favor of the Adcetris + CHP arm; safe & effective
• Adcetris (brentuximab vedotin- IV) is an ADC with anti-CD30 mAb- co-developed by Seattle Genetics and Takeda and has received FDA’s approval for 5 indications including r/r CD30+ Hodgkin lymphoma following ASCT- r/r sALCL- CD30+ CTCL

Ref: Seattle Genetics | Image: ValueWalk